Drug
ACT-539313
ACT-539313 is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_1
1
50%
Ph phase_2
1
50%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_2
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
NCT04753164
completedphase_1
A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects
NCT05254548
Clinical Trials (2)
Showing 2 of 2 trials
NCT04753164Phase 2
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
NCT05254548Phase 1
A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2